November 18, 2024 02:55 PM ESTUpdated 03:33 PM
R&D
Cell/Gene Tx

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

Jared Whitlock

Features Editor

Neu­ro­gene has re­leased de­tails of an ad­verse event in a clin­i­cal tri­al test­ing its gene ther­a­py for Rett syn­drome, af­ter news of the safe­ty is­sue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times